(VREX) Varex Imaging - Ratings and Ratios

Varex Imaging Corporation is a leading global provider of X-ray imaging components and solutions, operating through two core segments: Medical and Industrial. The Medical segment specializes in designing, manufacturing, and servicing a comprehensive range of X-ray imaging components, including X-ray tubes, digital detectors, ionization chambers, high-voltage connectors, and advanced software solutions such as image-processing workstations and 3D reconstruction software. These products are integral to various medical imaging applications, including computed tomography (CT), mammography, oncology, cardiac imaging, surgical procedures, dental radiography, and other diagnostic uses. The Industrial segment focuses on developing and manufacturing X-ray linear accelerators (Linatrons), X-ray tubes, digital detectors, high-voltage connectors, and coolers for industrial and security applications, such as airport baggage screening, cargo inspection at ports and borders, and non-destructive testing (NDT) in industrial settings. The company distributes its products through original equipment manufacturers (OEMs), independent service providers, distributors, and direct sales to end-users worldwide. With a global footprint, Varex Imaging operates in over 20 countries across North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Headquartered in Salt Lake City, Utah, the company was established in 2016 and has since become a key player in the X-ray imaging industry.

Ticker Symbol: VREX Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Health Care Equipment

Average Volume 20d: 616,243 Last Price: 12.85 SMA 20: 13.44 SMA 50: 13.89 SMA 200: 13.71 ATR: 0.60

Market Cap: $521.16M USD P/E: 0.00 P/E Forward: 60.24 P/B: 0.96 P/S: 0.63 RoE: -8.79

3-Month Forecast: Based on the provided data, VREX is currently trading below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The average true range (ATR) of 0.60 suggests moderate volatility. With a forward P/E of 60.24 and a negative return on equity (RoE) of -8.79, the stock may face headwinds in the near term. However, the low P/B ratio of 0.96 could signal undervaluation. Over the next three months, VREX is likely to remain under pressure due to its high forward valuation and negative profitability metrics. Investors should monitor the companys ability to improve its financial performance and reduce operational inefficiencies.